Instil Bio will present at the Jefferies Cell and Genetic Medicine Summit

Instil Bio will present at the Jefferies Cell and Genetic Medicine Summit

DALLAS, Sept. Feb. 19, 2022 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor-infiltrating lymphocyte, or TIL, therapies for the treatment of cancer patients, today announced that company management will participate in an upcoming investor conference: Jefferies Summit on Cells and Genetic MedicineCompany Overview and Q&A: Thursday, …

Instil Bio will present at the Jefferies Cell and Genetic Medicine Summit Read More »